Hairy Cell Leukemia (HCL)

Also known as: Leukemia, Hairy Cell / Hairy cell leukaemia / Hairy Cell Leukemia / Leukemias, Hairy Cell / Leukemic reticuloendotheliosis / Leukaemic reticuloendotheliosis

DrugDrug NameDrug Description
DB00242CladribineAn antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. [PubChem]
DB00105Interferon Alfa-2b, RecombinantInterferon alpha 2b (human leukocyte clone hif-sn 206 protein moiety reduced). A type I interferon consisting of 165 amino acid residues with arginine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent.
DB12688Moxetumomab PasudotoxCD22 is a lineage-restricted B-cell antigen that is expressed solely in on B-chronic lymphocytic leukemia, hairy cell leukemia, acute lymphocytic leukemiathe and Burkitt's lymphoma. The predecessor of Moxetumab pasudotox (MxP), named BL22, was first created based on the antibody RFB4 which specifically binds to CD22. This antibody was used to generate a recombinant immunotoxin in which a stabilized Fv segment by a disulfide bond is fused to the _Pseudomonas_ exotoxin A (PE38) which does not have the cell-binding portion.[A38864] MxP appears as an improved form of BL22 by the mutation of the Fv region and the antibody phage-displayed. As well the residues SSY in the heavy chain are mutated to THW.[A38864] It was developed by Astra Zeneca and FDA approved on September 13, 2018, after being granted the status of Fast Track, Priority Review and Orphan Drug designations.[L4568]
DB00552PentostatinA potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. [PubChem]
DrugDrug NamePhaseStatusCount
DB12688Moxetumomab Pasudotox1Completed1
DB12121Entospletinib1 / 2Recruiting1
DB08935Obinutuzumab1 / 2Recruiting1
DB00034Interferon Alfa-2a, Recombinant2Completed1
DB08881Vemurafenib2Active Not Recruiting1
DB00242Cladribine2 / 3Recruiting1
DB00125L-Arginine2 / 3Recruiting1
DB12688Moxetumomab Pasudotox3Active Not Recruiting1